ReviewExpert review of molecular diagnostics2014
DNA markers in molecular diagnostics for hepatocellular carcinoma.
Review in Expert review of molecular diagnostics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Circulating tumor DNA in management of primary liver malignancy: A review of the literature and future directions.Journal of surgical oncology · 2025Review
- Recent Advances in Biosensor Technology for Early-Stage Detection of Hepatocellular Carcinoma-Specific Biomarkers: An Overview.Diagnostics (Basel, Switzerland) · 2024Review
- Novel urine cell-free DNA methylation markers for hepatocellular carcinoma.Scientific reports · 2023Article
- Urinary biomarkers for hepatocellular carcinoma: current knowledge for clinicians.Cancer cell international · 2023Review
- Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings.Diagnostics (Basel, Switzerland) · 2023Review
- Detection ofDiagnostics (Basel, Switzerland) · 2021Article
- Epigenetically inactivated RASSF1A as a tumor biomarker.Bosnian journal of basic medical sciences · 2021Review
- Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma.American journal of translational research · 2019Article
- Liquid biopsies for hepatocellular carcinoma.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Development and Evaluation of Novel Statistical Methods in Urine Biomarker-Based Hepatocellular Carcinoma Screening.Scientific reports · 2018Article
- Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma.Hepatoma research · 2017Article
- Clinical applications of urinary cell-free DNA in cancer: current insights and promising future.American journal of cancer research · 2017Review
- Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.Journal of the National Cancer Institute · 2016Article
- A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy.Molecular pharmacology · 2016Article
- Building Classification Models with Combined Biomarker Tests: Application to Early Detection of Liver Cancer.Journal of statistical science and applicationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the one of the leading causes of cancer mortality in the world, mainly due to the difficulty of early detection and limited therapeutic options. The implementation of HCC surveillance programs in well-defined, high-risk populations were only able to detect about 40-50% of HCC at curative stages (Barcelona Clinic Liver Cancer stages 0 & 1) due to the low sensitivities of the current screening methods. The advance of sequencing technologies has identified numerous modifications as potential candidate DNA markers for diagnosis/surveillance. Here we aim to provide an overview of the DNA alterations that result in activation of cancer pathways known to potentially drive HCC carcinogenesis and to summarize performance characteristics of each DNA marker in the periphery (blood or urine) for HCC screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.